Med Lett Drugs Ther. 2010 Apr 5;52(1335):25-7.
Liraglutide (Victoza-Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral antidiabetic drugs such as metformin (Glucophage, and others) or glimepiride (Amaryl, and others). Liraglutide is not recommended for first-line therapy and is not approved for use with insulin.
利拉鲁肽（维达列汀-诺和诺德公司生产）是一种通过皮下注射给药的胰高血糖素样肽-1（GLP-1）受体激动剂，已获美国食品药品监督管理局（FDA）批准用于治疗2型糖尿病患者。它可单独使用，也可与口服抗糖尿病药物如二甲双胍（格华止等）或格列美脲（亚莫利等）联合使用。不推荐将利拉鲁肽用于一线治疗，且未获批与胰岛素联合使用。
